Q3 EPS Forecast for Capricor Therapeutics Reduced by Analyst

Key Points

• Roth Capital has lowered its Q3 2025 earnings per share estimate for Capricor Therapeutics from ($0.44) to ($0.66), while maintaining a "Buy" rating with a price target of $12.00.
• Capricor's current full-year earnings consensus estimate is ($1.21) per share, and analysts predict a return to profitability by 2026 with earnings expected at $1.40 EPS in Q3 2026.
• Despite recent downgrades, eight analysts still maintain a "buy" rating on the stock, which has a consensus price target of $22.56.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Investment analysts at Roth Capital lowered their Q3 2025 earnings estimates for Capricor Therapeutics in a research note issued on Tuesday, August 12th. Roth Capital analyst B. Pachaiyappan now forecasts that the biotechnology company will post earnings per share of ($0.66) for the quarter, down from their prior estimate of ($0.44). Roth Capital has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. Roth Capital also issued estimates for Capricor Therapeutics' Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.37) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at $1.40 EPS, Q4 2026 earnings at $3.01 EPS and FY2026 earnings at $3.47 EPS.

CAPR has been the topic of a number of other research reports. B. Riley started coverage on shares of Capricor Therapeutics in a research note on Thursday, June 26th. They issued a "buy" rating and a $21.00 target price on the stock. HC Wainwright reduced their target price on shares of Capricor Therapeutics from $77.00 to $24.00 and set a "buy" rating for the company in a research note on Friday, July 11th. Alliance Global Partners reiterated a "buy" rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Jones Trading reduced their target price on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a report on Wednesday, June 25th. Finally, Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $22.56.

Capricor Therapeutics Trading Up 2.3%

Shares of CAPR traded up $0.18 during mid-day trading on Thursday, reaching $7.96. The company had a trading volume of 1,253,578 shares, compared to its average volume of 1,923,061. The stock has a market cap of $363.93 million, a price-to-earnings ratio of -4.85 and a beta of 0.59. The firm has a fifty day simple moving average of $9.17 and a 200-day simple moving average of $10.96. Capricor Therapeutics has a fifty-two week low of $3.84 and a fifty-two week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $31,056,000. Geode Capital Management LLC raised its position in shares of Capricor Therapeutics by 6.8% in the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock valued at $9,565,000 after acquiring an additional 61,701 shares during the period. Woodline Partners LP raised its position in shares of Capricor Therapeutics by 15.8% in the 1st quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company's stock valued at $6,921,000 after acquiring an additional 99,384 shares during the period. Altium Capital Management LLC raised its holdings in Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock worth $9,853,000 after buying an additional 429,000 shares during the period. Finally, Octagon Capital Advisors LP bought a new position in shares of Capricor Therapeutics during the 1st quarter worth approximately $4,270,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.